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Influenza is one of the most common infectious diseases in travellers, 
especially in those returning from subtropical and tropical regions.
In late June 2018 an influenza A(H1N1)pdm09 virus infection was 
diagnosed in a 36-years-old man, returned from a travel in Shang-
hai and hospitalized at the Ospedale Policlinico San Martino, 
Genoa, Italy, with a diagnosis of fever and an uncommon clinical 
presentation characterised by a persistent leukopenia. Phyloge-
netic analysis revealed a closeness with influenza A(H1N1)pdm09 
strains circulating in the US in May-June 2018.
Prompt recognition of influenza infection led to a proper case 
management, demonstrating the crucial role of the continuous 
influenza surveillance programme.
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Introduction
Travels are associated with an increased risk of infec-
tious diseases, and influenza is one of the most frequent 
acquired infectious diseases in travellers [1].
Influenza is characterized by a seasonal pattern only 
in temperate climates, with a virus circulation usually 
observed during the cold season, coinciding with a pe-
riod that lasts from November to March in the Northern 
Hemisphere, and from April to October in the Southern 
Hemisphere. In tropical areas, however, influenza virus 
circulates at low levels all the year round [2]. Trips by 
air, ship or train facilitate the viral spread, depending of 
the length of the trip (0-1 infections could occur dur-
ing a 5 hours flight, 1-3 during an 11 hours flight and 
2-5 during a 17 hours flight) and the number of passen-
gers [3, 4]. The short incubation period and the high in-
fectivity of influenza (basic reproduction number - R0 
around 1.5) are the key reasons for the high frequency of 
influenza among travel-related diseases [1].
Fifty million people are estimated to travel to the trop-
ics each year and approximately half of these presents 
a travel-related health problem [5-8]. The proportion of 
influenza in travellers returning from subtropical and 
tropical regions ranges between 5% and 15% as reported 
by different studies [3, 9-11].
Case report
A 36-years-old man, returned four days earlier from a 
travel in Shanghai lasted 2 weeks, accessed to the Emer-
gency Department (ED) of Ospedale Policlinico San 
Martino, Genoa, Italy, on 28th June 2018 with a diagno-
sis of fever. The main clinical manifestation at the ED 
access was a hyperpyrexia started two days earlier (max-
imum body temperature: 39.5°C) responsive to paracet-
amol; associated symptoms were arthralgia, nausea and 
vomiting. The physical examination revealed a pharynx 
hyperaemia without tonsillar hypertrophy; no skin rash, 
headache or signs of nuchal rigidity were observed. His 
past medical history wasn’t characterized by any disease 
of note. In the ED a symptomatic therapy with paraceta-
mol (1 g/100 mL) was started.
In Table I the laboratory tests performed during patient’s 
hospitalization are reported. The tests performed at 
the ED revealed leukopenia (White Blood Cell count: 
3 x 109/L) and a modest increase in the levels of C-re-
active protein (13.6 mg/L), creatinine (1.2 mg/dL), and 
a low decrease of potassium (3.3 mEq/L) and alkaline 
phosphatase (ALP, 36 IU/L). Detection of malaria an-
tigens, Epstein-Barr virus (EBV) and cytomegalovirus 
(CMV) serology, blood culture and urine culture were 
performed and revealed only a previous EBV infection 
and a Escherichia coli count in the urine of 106 CFU/
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mL. The latter wasn’t treated because asymptomatic. No 
alterations were visible on the chest X-ray performed on 
28th June.
Upon admission at Clinical Immunology Unit, Depart-
ment of Internal Medicine of Ospedale Policlinico San 
Martino, the patient was substantially asymptomatic ex-
cept for a mild non-productive cough. In fact the fever, 
after the peak at 38.5°C on 28th June at ED, slowly de-
creased. Leukopenia was still present (from 28th June to 
the discharge at 10th July) and characterized by low lev-
els of neutrophil granulocytes (0.67 x 109/L at the nadir 
on 2nd July) and also a reduced reticulocyte count was 
observed from 3rd July (0.3%). Only on-demand therapy 
with paracetamol and metoclopramide was introduced.
A series of laboratory tests were performed during hos-
pitalization: blood cultures, sputum cultures, detection 
of Streptococcus pneumoniae and Legionella antigens 
in urine, parasites tests, detection of malaria antigens 
in blood samples, serological markers of infection by 
hepatitis A (HAV), B (HBV) and C (HCV), human 
immunodeficiency virus (HIV), Zika virus, Parvovi-
rus, Salmonella typhi and paratyphi, Brucella, Proteus, 
Tab. I. Laboratory tests performed during patient’s hospitalization (Emergency Department and Clinical Immunology Unit, Ospedale Policlinico 
San Martino).
Variable Reference range Day 1(ED)
Day 2 
(ED) Day 5 Day 6 Day 7 Day 8 Day 12
WBCs 4.50-9.80 x 109/L 3 2.72 1.76 1.76 2.35 3.16 4.4
RBCs 4.5-5.9 x 1012/L 5.2 5 4.9 4.6 4.5 4.5 4.9
Hemoglobin 135-175 g/L 144 141 139 130 124 131 143
Hematocrit 39-51% 44 43.1 41.3 38.2 37.2 37.7 42.1
MCV 80-100 fL 85.3 85.9 83.6 82.9 83.3 83 85.4
MCH 26-32 pg 27.9 28.1 28.1 28.3 27.8 28.9 29
MCHC 320-360 g/L 327 327 337 341 334 348 340
RDW 11.5-14.5% 12.8 12.8 12.2 11.8 11.9 11.8 12.6
Platelet 130-430 x 109/L 143 148 113 114 131 157 278
Neutrophils 1,80-7,80 x 109/L 2 1.7 0.67 0.74 1.22 1.63 2.7
Neutrophils 40,0-70,0% 62 37.9 41.9 51.8 51.7 61.8
Lymphocytes 1,10-4,80 x 109/L 0.7 0.88 0.82 0.93 1.22 1.4
Lymphocytes 19,0-48,0% 24.4 49.9 46.9 39.7 38.5 32.2
Monocytes 0,20-0,96 x 109/L 0.4 0.07 0.07 0.08 0.09 0.2
Monocytes 3,4-12,0% 13.2 4 3.8 3.2 2.8 4.5
Eosinophils 0,00-0,50 x 109/L 0 0.02 0.03 0.06 0.12 0.1
Eosinophils 0,0-8,0% 0.1 0.9 1.9 2.7 3.8 1.3
Basophils 0,00-0,20 x 109/L 0 0.02 0.03 0.02 0.02 0
Basophils 0,0-1,5% 0.3 1.1 1.6 0.7 0.7 0.2
LUC 0,0-4,0% 6.2 3.9 1.9 2.4
Reticulocytes 0,7-1,7 x 100 RBCs 0.3 0.5 0.6
Creatinine 0,67-1,17 mg/dL 1.2 1.2 1 1
Prothrombin time % (10-13 sec) 73 82 101 101
Prothrombin time INR 0.80-1.20 1.24 1.15 0.99 0.99
Activated partial 
thromboplastin time 28,0-40,0 sec 34.8 33.7 33.2 31.9
Total bilirubin 0.20-1.20 mg/dL 0.46 0.35 0.30 0.27
Sodium 135-150 mmol/L 136 137 141
Potassium 3,5-5 mmol/L 3.3 3.5 4
Chloride 90-120 mEq/L 99 102
Calcium 8,5-11,0 mg/dL 8.4 9.1
Phosphorus 2.5-4.5 mg/dL 3.7 3.8
Magnesium 1.9-2.5 mg/dL 2.1 2.1
Glucose 65-110 mg/dL 97 96
Albumin 34-50 g/L 36.4 40.3
C-Reactive Protein 0-5 mg/L 13.6 9.6 3.2 3.2
ALP 50-116 U/L 36 38 30 28
ALT 0-40 U/L 26 23 18 16
gGT 11-50 U/L 13 19 16
WBCs: White Blood Cells count. RBCs: Red Blood Cells count. MCV: Mean Corpuscular Volume. MCH: Mean Cell Hemoglobin. MCHC: Mean Corpuscular 
Hemoglobin Concentration. RDW: Red cell Distribution Width. LUC: Large Unsustained Cells. ALP: ALkaline Phosphatase. ALT: ALanine aminoTranspherase. 
gGT: gamma GlutamylTranspherase. INR: International Normalized Ratio.
Values out of range are in bold and underlined.
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Schistosoma and Leishmania. Nasopharyngeal swab for 
respiratory viruses and bacteria was performed for the 
first time on 2nd July and resulted positive on 4th July, re-
vealing the presence of influenza A(H1N1)pdm09 virus 
and Haemophilus influenzae.
Antiviral therapy with oseltamivir (150 mg/day) was 
started on 4th July and the patient was concurrently iso-
lated. The general outcome was good and the patient was 
discharged at the end of antiviral therapy on 10th July, 
with a diagnosis of influenza A(H1N1)pdm09 infection 
and transient neutropenia probably due to infection. The 
patient received the recommendation to limit contact with 
people at greater risk (cardiopathic, pneumopathic, el-
derly in general, immunocompromised people, pregnant 
women, infants) and to wear the mask until the result of 
the nasopharyngeal swab performed at the discharge. This 
last resulted negative three days later, on July 13th.
Phylogenetic analysis of the virus strain were performed 
as previously described  [12] between July and August 
2018 and revealed a similarity with viruses isolated 
in the US in May and June 2018 and characterized by 
T120A mutation (Fig. 1).
Fig. 1. Phylogenetic analysis of the hemagglutinin (HA) nucleotide sequences from influenza A(H1N1)pdm09 viruses. The phylogeny tree 
was generated by the neighbor-joining method with 1000 bootstrap replicates. Ligurian strains (underlined), WHO recommended candidate 
vaccine for 2017/2018 and 2018/2019 Northern Hemisphere influenza season (bold, underlined) and reference strains (bold).
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Discussion
Worldwide, in the period June-July 2018 seasonal influ-
enza type A viruses accounted for the majority of detec-
tions. A(H1N1)pdm09 prevailed over A(H3N2) viruses. 
In temperate zone influenza activity was at inter-seasonal 
levels, whereas in tropical countries of Central America, 
South America, African region and Asia influenza activ-
ity remained low in the same period. In particular viro-
logical surveillance in China from week 18 to week 31 
of 2018 revealed that influenza subtype A(H1N1)pdm09 
virus was the most frequent detected  [2]. However, no 
influenza virus isolation has been notified in Shanghai 
in the same period [13].
Influenza infection must be taken into account in differ-
ential diagnosis in every season and in any patients with 
acute respiratory disease coming from an intercontinen-
tal travel, even though with an atypical clinical presen-
tation. In our case, the diagnosis of influenza infection 
settled diagnostic doubts, therefore providing the better 
patient management. 
Continuous virological surveillance allows constant 
monitoring of circulating influenza viruses, representing 
a key tool for characterization and selection of influenza 
strains to be included in vaccine composition, as well 
as for potential detection of new viral strains, including 
those carrying a pandemic risk.
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